Establishment of novel anti-cancer concept overcoming drug resisitancies.

2019 Fiscal Year Final Research Report

• Project/Area Number: 17H03597
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Kyoto University
• Principal Investigator: Kamikubo Yasuhkiko 京都大学, 医学研究科, 特定教授 (60548527)
• Co-Investigator(Kenkyū-buntansha): 足立 壯一 京都大学, 医学研究科, 教授 (10273450)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: 人工遺伝子スイッチ法 / スパコンシミュレーション法 / RUNX / p300 / Ras Gene Module / RTK / 難治性白血病 / 肺癌

Outline of Final Research Achievements

A: Development of a common tumor growth mechanism (RGM: Ras Gene Module) control method using an artificial gene switch method
A RTK (Receptor Tyrosine Kinase) control method was discovered. The oncogene fusion control method was discovered. We have developed a novel solid tumor stem cell / tumor marker control method.
B: Simulation drug development using supercomputer K: Development of p300-RUNX1 inhibitor; Candidate inhibitors were extracted from various cancers (prostate cancer DNPC), TNBC lung cancer, Kras mutant colon cancer and pancreatic cancer. Through the construction of an innovative anti-tumor concept that overcomes the resistance of molecular target drugs by A.B, we have achieved a fusion development method of human-school gene switch method and supercomputer simulation method.

Free Research Field

腫瘍生物学

Academic Significance and Societal Importance of the Research Achievements

革新的な人工遺伝子スイッチ法によりRUNXを転写抑制することにより、RUNXのターゲット遺伝子を消失させることに成功した。これは世界には未だない方法である。スパコンシミュレーション法を用いて、RUNXとp300を同時に抑制できる低分子化合物を創薬計算し抽出した。この2つの方法を融合し、分子標的薬耐性を克服する革新的抗腫瘍コンセプトの構築を行ったことは学術的意義と社会的意義を有する。